Personalis, Inc. (PSNL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Personalis, Inc. (PSNL) Healthcare & Pipeline Overview

Personalis, Inc. is a cancer genomics company offering advanced sequencing and data analysis solutions, including the NeXT Platform, to biopharmaceutical companies, universities, and research institutions. The company focuses on enabling the development of personalized cancer therapies and advancing large-scale genetic research programs within the competitive healthcare diagnostics market.

What Is the Investment Thesis for PSNL?

The company's NeXT platform and related services cater to the growing demand for personalized cancer therapies and advanced genetic research. With a market capitalization of $0.60 billion, Personalis operates in a high-growth sector driven by increasing investments in cancer research and precision medicine. Key value drivers include the expansion of its NeXT platform capabilities, strategic collaborations with biopharmaceutical companies and research institutions, and the potential for increased adoption of its liquid biopsy solutions. However, the company's negative profit margin of -148.1% and a high beta of 2.21 indicate significant financial risks and market volatility. Successful execution of its growth strategies and improved financial performance are crucial for realizing its long-term potential.

Based on FMP financials and quantitative analysis

PSNL Key Highlights

Market Cap of $0.60 billion reflects investor valuation of Personalis' potential in the cancer genomics market.

• Gross Margin of 13.7% indicates the profitability of Personalis' core services after accounting for direct costs.
• Profit Margin of -148.1% highlights the company's current challenges in achieving profitability despite revenue generation.
• Beta of 2.21 suggests higher volatility compared to the overall market, indicating potential for significant price fluctuations.
• Partnerships with Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center demonstrate strategic collaborations to expand research and market reach.

Who Are PSNL's Competitors?

PSNL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are PSNL's Key Strengths?

Advanced NeXT Platform for comprehensive genomic analysis.

• Strategic partnerships with leading research institutions.
• Diverse product portfolio for tumor profiling and personalized treatment.
• Expertise in sequencing and data analysis.

What Are PSNL's Weaknesses?

Negative profit margin indicating financial challenges.

• High beta suggesting market volatility.
• Reliance on partnerships for research and development.
• Limited geographic presence.

What Could Drive PSNL Stock Higher?

Expansion of NeXT Platform capabilities with AI and machine learning in Q3 2026.

• Announcement of new strategic partnerships with biopharmaceutical companies in Q4 2026.
• Increased adoption of liquid biopsy solutions for early cancer detection.
• Geographic expansion into emerging markets in Asia-Pacific.

What Are the Key Risks for PSNL?

Negative return on equity (-43.5%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
• Insider selling — insiders were net sellers of roughly $6.9M recently.
• Intense competition from established diagnostic companies like Exact Sciences and Guardant Health.
• Regulatory hurdles and reimbursement challenges affecting market access.
• Technological advancements by competitors leading to loss of market share.
• Economic downturn affecting research funding and customer spending.
• Negative profit margin indicating financial instability.

What Are the Growth Opportunities for PSNL?

• Expansion of NeXT Platform Capabilities: Personalis can enhance its NeXT platform by incorporating advanced data analytics and machine learning algorithms to improve the accuracy and efficiency of tumor profiling. The global market for AI in drug discovery is projected to reach $4.0 billion by 2027, presenting a significant opportunity for Personalis to integrate AI-driven solutions into its platform. This expansion can attract more biopharmaceutical clients seeking comprehensive genomic insights for drug development, with an estimated timeline of 1-2 years for implementation.
• Strategic Partnerships with Biopharmaceutical Companies: Personalis can forge deeper collaborations with biopharmaceutical companies to co-develop personalized cancer therapies and companion diagnostics. The market for companion diagnostics is expected to reach $7.8 billion by 2028. By partnering with leading pharmaceutical firms, Personalis can secure long-term contracts and revenue streams, while also gaining access to valuable clinical data and market expertise. These partnerships can be established within the next 12-18 months.
• Increased Adoption of Liquid Biopsy Solutions: Personalis can drive the adoption of its NeXT Liquid Biopsy for personalized tumor tracking by demonstrating its clinical utility and cost-effectiveness. By showcasing the benefits of its liquid biopsy solutions in early cancer detection and treatment monitoring, Personalis can expand its market share and generate recurring revenue from patient monitoring programs. This expansion can occur over the next 2-3 years.
• Geographic Expansion into Emerging Markets: Personalis can expand its geographic footprint by entering emerging markets with high unmet needs for cancer diagnostics and treatment. The Asia-Pacific region is expected to be the fastest-growing market for cancer diagnostics, driven by increasing healthcare expenditure and a rising prevalence of cancer. By establishing partnerships with local hospitals and research institutions, Personalis can gain access to new patient populations and revenue streams within the next 3-5 years.
• Development of Novel Biomarkers and Drug Targets: Personalis can leverage its ACE platform to identify novel biomarkers and drug targets for cancer therapy. The market for biomarker discovery is projected to reach $6.2 billion by 2027. By developing innovative biomarkers and drug targets, Personalis can attract research funding and licensing agreements, while also contributing to the advancement of cancer treatment. This development can be achieved through ongoing research and development efforts over the next 3-5 years.

What Are PSNL's Competitive Advantages?

• Proprietary NeXT Platform: Offers comprehensive data analysis for tumor profiling.
• Strategic Partnerships: Collaborations with Mayo Clinic and other institutions enhance research capabilities.
• Advanced Sequencing Technology: Provides accurate and efficient genomic analysis.
• Comprehensive Product Portfolio: Offers a range of solutions for tumor profiling and personalized treatment.

What Does PSNL Do?

Personalis, Inc., founded in 2011 and headquartered in Menlo Park, California, operates as a cancer genomics company. It provides sequencing and data analysis services aimed at supporting the development of cancer therapies and facilitating large-scale genetic research programs. The company's core offering is the NeXT Platform, which delivers comprehensive data analysis of a tumor and its immune microenvironment from limited tissue or plasma samples. This platform is complemented by a suite of products including ImmunoID Next for tumor profiling from tissue, NeXT Liquid Biopsy for tumor profiling from plasma, and NeXT Personal, a liquid biopsy solution for personalized tumor tracking. Personalis also offers NeXT Dx Test, a genomic cancer profiling test designed to enable composite biomarkers for cancer treatment, as well as NeXT SHERPA and NeXT NEOPS for neoantigen prediction. Additionally, the company provides the ACE platform, which supports clinical and therapeutic applications such as neoantigen prediction, biomarker identification, and novel drug target selection. Personalis serves a diverse clientele, including biopharmaceutical companies, universities, non-profit organizations, and government entities. The company has established partnerships with institutions such as Mayo Clinic, MapKure, LLC, SpringWorks Therapeutics, Inc., and Moores Cancer Center, enhancing its research and development capabilities and broadening its market reach.

What Products and Services Does PSNL Offer?

• Provides sequencing and data analysis services for cancer therapies.
• Offers the NeXT Platform for tumor and immune microenvironment analysis.
• Provides ImmunoID Next for tumor profiling from tissue samples.
• Offers NeXT Liquid Biopsy for tumor profiling from plasma samples.
• Provides NeXT Personal for personalized tumor tracking.
• Offers NeXT Dx Test for genomic cancer profiling.
• Provides NeXT SHERPA and NeXT NEOPS for neoantigen prediction.
• Offers ACE platform for clinical and therapeutic applications.

How Does PSNL Make Money?

• Provides sequencing and data analysis services to biopharmaceutical companies.
• Generates revenue from sales of its NeXT Platform and related products.
• Partners with universities and research institutions for collaborative projects.
• Offers genomic cancer profiling tests for personalized treatment.

What Industry Does PSNL Operate In?

Personalis, Inc. operates within the rapidly evolving medical diagnostics and research industry, specifically focusing on cancer genomics. The market is characterized by increasing demand for personalized medicine and advanced sequencing technologies. Competitive landscape includes companies like Exact Sciences (EXAS) and Guardant Health (GH), which offer similar diagnostic and genomic profiling services. The industry is driven by technological advancements, increasing investments in cancer research, and a growing emphasis on early detection and targeted therapies. Personalis's NeXT platform positions it to capitalize on these trends by providing comprehensive genomic analysis for cancer treatment and research.

Who Are PSNL's Key Customers?

• Biopharmaceutical companies developing cancer therapies.
• Universities and research institutions conducting genetic research.
• Non-profit organizations focused on cancer research.
• Government entities involved in healthcare and research.

Over the past six months, Personalis, Inc. insiders filed 30 SEC Form 4 transactions — 19 sales and 11 purchases. On net that is roughly 509K shares disposed (about $6.9M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: Personalis, Inc.

Revenue for Personalis, Inc. came in at $22.4M during Q2 FY2026, a 44.5% improvement versus the preceding quarter. The company recorded a net loss of $31.7M, with diluted EPS of $-0.30. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare. Across the four most recent quarters, PSNL averaged $-0.27 in diluted EPS.

PSNL Valuation & Market Position

Analyst price targets span from $9.00 to $17.00, with a consensus of $14.95. At the current price of $16.33, that implies roughly 8% downside from the consensus target. Relative to its peer group, PSNL's quantitative score of 22/100 is below the peer average of 52/100.

Return on equity for Personalis, Inc. stands at -43.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -29.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -9.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 6.61 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -9.4%, the inverse of the P/E and a quick read on earnings relative to price.

Personalis, Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 10.39 places it in the safe zone, indicating low near-term bankruptcy risk.

Personalis, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 5.7% below estimates on average.

Company Profile

Personalis, Inc. operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Fremont, US. The company is led by CEO Christopher Hall. PSNL has traded publicly since 2019.

PSNL Financials

PSNL Latest News

PSNL Analyst Consensus

PSNL MoonshotScore

Personalis, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources